Best-case Series for the Use of Immuno-Augmentation Therapy and Naltrexone for the Treatment of Cancer

Published in: Evidence Report/Technology Assessment: no. 78 (Prepared by the Southern California/RAND Evidence-based Practice Center under contract No. 290-97-0001). AHRQ Publication No. 03-E029. Agency for Healthcare Research and Quality, Rockville, MD., Apr. 2003

by Paul G. Shekelle, Ian D. Coulter, Mary L. Hardy, Sally C. Morton, Joya T. Favreau, James Gagne, Adelaide Coulter, Sydne Newberry, Jay Udani, Elizabeth Roth, et al.

Read More

Access further information on this document at

This article was published outside of RAND. The full text of the article can be found at the link above.

For this study, the researchers used criteria developed by the Office of Cancer Complementary and Alternative Medicine (OCCAM), a part of the National Cancer Institute. These criteria require the following: Documentation of the diagnosis of cancer. The patient's cancer should be documented by obtaining tumor tissue and having it examined by a pathologist. The pathologist's report should be included in the case summary. Evaluation of the appropriate antitumor endpoint. The only reliable antitumor endpoint that can be documented in a best-case series is a demonstrable and reproducible reduction of tumor size. Tumor measurements are made before treatment, during treatment, and after treatment is complete. An objective response is considered to be a decrease of at least 50 percent in the area of the tumor (i.e., the cross product of the diameters) with no increase in size of any other lesions. The patient must not be receiving any other treatment for his/her cancer. To document an antitumor effect based upon individual patient histories, the patient must have a documented, measurable tumor just before the CAM modalities are given. While the CAM modalities themselves may have multiple components, they must not be given together with any other cancer treatments. A record of previous anti-cancer treatments. Documentation of sites of the cancer. At least one recurrent or metastatic cancer should be documented histologically. The date at which recurrence or metastatic disease was first noted should be provided. Description of the patient's general medical condition. The age, sex, and any other previous or concurrent illnesses or significant medical conditions should be carefully documented. Description of the treatment administered. The treatment that was felt to result in the antitumor response should be described.

This report is part of the RAND Corporation External publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

Our mission to help improve policy and decisionmaking through research and analysis is enabled through our core values of quality and objectivity and our unwavering commitment to the highest level of integrity and ethical behavior. To help ensure our research and analysis are rigorous, objective, and nonpartisan, we subject our research publications to a robust and exacting quality-assurance process; avoid both the appearance and reality of financial and other conflicts of interest through staff training, project screening, and a policy of mandatory disclosure; and pursue transparency in our research engagements through our commitment to the open publication of our research findings and recommendations, disclosure of the source of funding of published research, and policies to ensure intellectual independence. For more information, visit

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.